Zoetis Inc. (NYSE:ZTS) Shares Acquired by Webster Bank N. A.

Webster Bank N. A. boosted its position in Zoetis Inc. (NYSE:ZTS) by 89.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 174 shares of the company’s stock after acquiring an additional 82 shares during the quarter. Webster Bank N. A.’s holdings in Zoetis were worth $29,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC increased its position in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares in the last quarter. Independence Bank of Kentucky lifted its holdings in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares in the last quarter. Private Wealth Management Group LLC purchased a new position in Zoetis in the fourth quarter valued at about $33,000. Ramirez Asset Management Inc. acquired a new position in Zoetis during the 3rd quarter worth approximately $35,000. Finally, Gladius Capital Management LP acquired a new stake in Zoetis in the fourth quarter valued at approximately $40,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity

In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS traded down $3.10 during trading hours on Friday, reaching $173.36. The company’s stock had a trading volume of 4,189,580 shares, compared to its average volume of 2,374,760. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The business has a 50-day simple moving average of $168.69 and a 200 day simple moving average of $178.81. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock has a market cap of $79.10 billion, a PE ratio of 33.40, a PEG ratio of 2.74 and a beta of 0.88.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period last year, the company earned $1.31 earnings per share. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Analysts Set New Price Targets

Several research firms recently issued reports on ZTS. HSBC dropped their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Barclays cut their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus reduced their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Finally, The Goldman Sachs Group cut their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.